Psoriasis clinical trials at UCSF
7 in progress, 5 open to eligible people
Psoriasis causes red, itchy skin patches. UCSF is testing how different treatments affect immune cells in psoriasis. One study uses the drug Guselkumab to see its impact on scalp psoriasis. Another trial looks at how sleep affects people with moderate-to-severe psoriasis.
Correction of Psoriatic T Cell Signatures by Deucravacitinib
open to eligible people ages 18-75
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
San Francisco, California
Guselkumab Immunogenetics
open to eligible people ages 18 years and up
This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.
San Francisco, California
Immune Spatial Features of Guselkumab Cutaneous Response
open to eligible people ages 18 years and up
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
San Francisco, California
Psoriatic Immune Response to Tildrakizumab
open to eligible people ages 18-75
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
San Francisco, California
Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis
open to eligible people ages 18 years and up
Getting enough sleep is important for maximizing health and well-being. When it comes to health, sleep is as vital as regular exercise and eating a balanced diet. Not getting enough sleep can lead to health problems like heart attacks, diabetes, and …
San Francisco, California
JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
Sorry, in progress, not accepting new patients
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Fresno, California and other locations
Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-to-severe body psoriasis or predominant moderate-to-severe scalp psoriasis by assessing improvements …
Fresno, California and other locations
Our lead scientists for Psoriasis research studies include Raymond Cho Wilson Liao, MD Tina Bhutani, MD, MAS.
Last updated: